ScreenPoint Medical has announced the acquisition of Biomediq A/S, a research company specializing in quantitative imaging biomarkers. The acquisition follows a decade of collaboration between the companies on image-based risk assessment and aims to integrate breast cancer risk assessment capabilities into ScreenPoint’s Transpara Breast AI platform.
Biomediq’s technology enables automatic computer-based analysis of 2D and 3D mammograms for future breast cancer risk analysis. The technology utilizes a Mammographic Texture Risk biomarker that identifies tissue heterogeneity associated with both short- and long-term breast cancer risk.
A 2023 Radiology publication demonstrated the potential of combining Transpara’s capabilities with Biomediq’s approach. The study showed that merging Transpara-based lesion detection, volumetric density assessment, and quantitative texture analysis improved risk prediction. Andreas D. Lauritzen, PhD, the study’s first author, will join ScreenPoint to advance Transpara’s risk assessment capabilities.
“Risk-stratified screening has long been proposed to optimize screening for patients and better use resources,” said Professor Nico Karssemeijer, co-founder and Chief Scientific Officer of ScreenPoint Medical. “We are excited to add the Biomediq risk analysis technology to enhance the capabilities of Transpara to improve performance for mammography-based breast cancer risk assessment. This is a game-changing step in providing accurate and consistent breast cancer detection and care for all women.”
Professor Mads Nielsen, co-founder of Biomediq, commented on the acquisition: “our long time collaboration and deep relationship with the ScreenPoint team have been grounded in our shared vision for better screening for women. Joining our technologies to support radiology workflow and support care for women is an exciting fruit of this deep and complementary collaboration.” Nielsen will continue as an advisor to the expanded ScreenPoint team.
Transpara recently released version 2.1, which includes automated breast density assessment options and temporal comparison capabilities allowing analysis of suspicious areas against up to three priors over six years. The platform has been validated through over 35 peer-reviewed publications and studies show it can help detect up to 45% of interval cancers earlier while reducing workload and optimizing workflow.
